RxDoctor Payments Data

Elizabeth Bradford Bell, MD

Plastic Surgery within the Head & Neck · Omaha, NENPI 1720321342

Payments from drug & device makers

What this record shows

12 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 55.6% of the total. Reporting peaked in 2023 at $925 and has fallen 71.5% since, to $263 in 2025.

$1,808in general payments, 2019–2025

Across 22 payments — averaging $82.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$1K
  • Stryker$340
  • Integra Lifesciences Corporation$138
  • Johnson & Johnson$112
  • Axogen$50
  • Baxter Healthcare$47
  • plus $116 from 6 others

What the payments were for

  • Travel & lodging$74441%
  • Food & beverage$1,06459%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few plastic surgery within the head & neck providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$98,200
Medicare patients
189
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin21$259
Levothyroxine Sodium16$138

Paid to pharmacies, not to this prescriber.

Other plastic surgery within the head & neck in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →